In the first half of 2023, Surface expects to present updated clinical data from the ongoing Phase 2 trials investigating SRF388 in liver and lung cancer. Initial safety and efficacy data from the ongoing SRF114 Phase 1/2 clinical study are anticipated in 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SURF:
- Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
- Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference
- Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue